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Abstract
Rationale: The recreational use of MDMA/Ecstasy (3,4-methylenedioxymethamphetamine)
is associated with many psychobiological problems, but there is a paucity of data on how
these relate to the level of past use. Objectives: to assess the incidence of Ecstasy-attributed
problems as reported by novice, moderate and heavy users. Methods: 763 unpaid volunteers
took part in a WWW study of recreational drug use. This report is based on the 282 Ecstasy
users from that sample, who comprised 109 novice users (1-9 occasions), 136 moderate users
(10-99 occasions), and 36 heavy users (+100 occasions). Yes/no responses were
automatically recorded to a series of questions covering psychobiological problems
experienced when drug-free, which were attributed by the respondents to their Ecstasy use.
Results: Depression, memory problems, anxiety, mood fluctuation, poor concentration,
infections, tremors/twitches, and weight loss, were all significantly associated with the extent
of Ecstasy use. Thus memory problems attributed to Ecstasy were reported by 19% of novice
users, 52% of heavy users, and 73% of heavy users (Chi-Square 42.74, df=2, p<0.001); many
of the other variables showed similar trends. Conclusions: The incidence of problems
attributed to Ecstasy use, is directly related to the number of occasions it has been used.
keywords: Ecstasy, mdma, memory, mood, depression.
3The recreational use of MDMA is associated with a wide range of psychobiological
problems: memory deficits, raised psychiatric symptom profiles, altered patterns of eating,
sleep and sex (McCann et al, 2000; Parrott, 2000, 2001). Most previous research has
compared Ecstasy users with non-user controls (Rodgers, 2000; Heffernan et al, 2001;
Morgan, 1999), although a few studies have directly compared light and heavy Ecstasy users.
Two investigations found no significant cognitive performance differences between novice
and regular users (Parrott et al, 1998; Parrott and Lasky, 1998), although Fox et al (2001)
found a significant association between past Ecstasy usage and the extent of cognitive deficits
on two tasks. Schifano et al (1998) reported that Ecstasy users with psychopathological
problems (eg. depression, bulimia, impulse control disorder), had taken the drug on
significantly more occasions than the non-problematic users. Parrott et al (2000) found the
highest psychiatric symptom scores in heavy Ecstasy users, while the symptom profiles for
moderate users were closer to those for the non-user controls. Disorders of eating/appetite,
sleep, and sexual interest/pleasure have also been reported (Parrott et al, 2002; Schifano et al,
1998; Topp et al, 1999), but there is little data on their occurrence in novice versus more
experienced users. The aim of the current study was to compare the incidence of problems
attributed to Ecstasy use, reported by novice, moderate, and heavy users.
Materials and Methods.
General procedures and participant characteristics:
This report is based upon a WWW study into the self-rated memory abilities of young
recreational drug users and non-users. The data were acquired through a web-site hosted on the
University of Westminster web server and accessible via a number of different addresses (e.g.
www.drugresearch.org.uk). The participants were recruited through a variety of techniques,
such as announcements to students at colleges and universities, and recruitment notices
posted on relevant Internet sites. Each unpaid volunteer completed a number of demographic
items and questionnaires related to their memory abilities and past drug use. An initial report
on the memory questionnaire findings from the preliminary cohort has already been published
(Rodgers et al, 2001); this is being followed by a final report on the overall memory
questionnaire findings from the total sample of 763 participants (Rodgers et al, submitted).
4Each unpaid volunteer completed a modified version of the University of East London (UEL)
Recreational Drug Use Questionnaire (Parrott et al, 2000), to indicate their past drug experience.
For Ecstasy/MDMA the five response choices were: 'never in my life', '1-9 occasions', '10-99
occasions', 'more than 100 occasions', and 'prefer not to answer'. All participants chose to
answer the question, with most (n=481) indicating that they had never used Ecstasy. The current
report is based solely on the 282 Ecstasy users, who comprised: 109 novice users (1-9
occasions), 136 moderate users (10-99 occasions), and 37 heavy users (+100 occasions). The
Ecstasy users also indicated their normal MDMA dose per occasion, and the highest number of
tablets ever taken in one week, both of which differed significantly across subgroups. Thus
100% of novice users normally took 1-2 tablets per occasion, compared with 84% of moderate
users, and 62% of heavy users; a normal dose of 3-4 tablets/occasion was reported by 0% of
novice users, 13% of moderate users, and 24% of heavy users; while a normal dose of +4
tablets/occasion was reported by 0% of novice users, 3% of moderate users, and 14% of heavy
users (Chi-Square 39.40, df=4, p<0.001). With reference to the most tablets ever taken in one
week, a maximum of 1-2 tablets/ week was reported by 91% of novice users, 23% of moderate
users, and 0% of heavy users; a maximum of 3-9 tablets/week was reported by 9% of novice
users, 68% of moderate users, and 65% of heavy users; while a maximum of +10 tablets/week
was reported by 0% of novice users, 9% of moderate users, and 35% of heavy users (Chi-Square
169.99, df=4, p<0.001; see Scholey et al, submitted).
Assessment measures:
Each participant was asked to indicate whether or not they had experienced any of a list of
eleven problems while 'off-drug' which they attributed to their Ecstasy use. The questions
were based upon the literature on psychobiological problems in Ecstasy users, and covered
cognitive deficits (poor memory, poor concentration), mood changes (depression, anxiety,
mood fluctuation, impulsivity), and physiological/medical disorders (weight loss, infections,
tremors/twitches, poor sleep, sexual problems). Each question required a binary yes/no
response.
Data analysis:
The data was analysed by 2x3 Chi-Square, with two levels of response (yes/no), and three
drug usage categories (novice, moderate, and heavy).
5Results
The percentage of novice, moderate, and heavy recreational Ecstasy/MDMA users (1-9, 10-
99, and +100 occasions) reporting problems which they attributed to the use of Ecstasy, are
shown in Table 1. This table also presents the Chi-square values for the binary responses from
the three usage groups.
- Table 1 near here -
Discussion
Memory problems were strongly associated with past Ecstasy usage (Table 1), since they
were reported by 19% of novice users, 52% of moderate users, and 73% of heavy users (Chi-
Square = 42.76, df = 2, p<0.001). This is consistent with the extensive literature on memory
disorders in Ecstasy users, with significant deficits found across a wide range of performance
tasks and questionnaires (Gouzoulis-Meyfrank et al, 2000; Heffernan et al, 2001; Morgan,
1999, 2000; Parrott et al, 1998; Parrott, 2001; Rodgers et al, 2000, 2001). The findings are
also consistent with Fox et al (2001), who found that spatial recall was inversely related to
past Ecstasy usage, and that verbal recognition was also worst in the heavy users. The data
also show that many Ecstasy users are fully aware of their memory difficulties. Depression,
anxiety, and mood fluctuations attributed to Ecstasy, were also strongly related to the number
of occasions it had been used; they were reported by 60-80% of heavy users, 54-70% of
moderate users, and 32-38% of novice users (Table 1). Curran and Travill (1997) reported
'mid-week blues' in weekend Ecstasy users, with some individuals reporting clinically
borderline levels of depression in the days following MDMA. Parrott and Lasky (1998) noted
considerable mood fluctuation over the week when Ecstasy was taken, with high moods on-
drug followed by sadness and unsociability in the days afterwards, due probably to
monoaminergic depletion (Parrott, 2001). Depression is however not just a rebound
phenomenon, but is also reported by former users 'now leading relatively drug-free lives'
(MacInnes et al, 2001, p181).
6Other studies have reported raised psychiatric symptom profiles in recreational Ecstasy
polydrug users (Schifano et al, 1998; Parrott et al, 2000, 2002). Topp et al (1999, p112) found
a range of psychobiological, occupational and medical complaints in regular users: 'On
average, subjects reported eight physical and four psychological side-effects which they
perceived as being due, at least in part, to their use of Ecstasy'. The current findings confirm
the diversity of problems experienced by heavy Ecstasy users, including weight loss,
tremors/twitches, and infections (Table 1). Although reported by a significantly higher
proportion of heavy users, they were also occasionally noted by novice users. This may reflect
differences in individual sensitivity, with some individuals reporting adverse reactions despite
having taken the drug just a few times. Three variables were not significantly related to past
usage: impulsivity, poor sleep, and sexual problems, although the pattern of reported
problems did conform to the same trend (Table 1). Many regular clubbers display irregular
patterns of rest and sleep, thus it was not surprising that poor sleep was reported by all
groups. McCann et al (2000) noted that the sleep architecture of abstinent Ecstasy users often
varied from those of non-users, although sometimes in contrasting ways. Similarly while
some MDMA users report acute difficulties in sexual activity, others report acute sexual
enhancement (Zemishlany et al, 2001). However a minority of regular Ecstasy users report
long-term reductions in sexual interest and/or ability. Topp et al (1999) found that 12% of
regular users reported 'loss of sex urge' during the last 6 months. Parrott et al (2002) found
that 14% of heavy users complained of 'loss of sexual interest or pleasure'.
There are several limitations to the current study which are characteristic of all recreational
Ecstasy drug research. Thus there was no control over which drugs people had taken, nor the
degree to which 'Ecstasy' tablets were MDMA or other dance drugs. Regular clubbers often
display irregular circadian rhythms, with prolonged periods of dancing, disrupted sleep,
inadequate rest, and poor nutrition. All these factors may affect their health, and general well-
being (Parrott et al, 2001). For a fuller discussion of these issues the reader is referred to
Curran (2000), while they are also discussed in the following reviews: Morgan (2000),
Schifano (2000), and Parrott (2000, 2001). Heavy Ecstasy users often take a variety of
psychoactive drugs, not only illicit compounds such as amphetamine, cocaine or LSD, but
also legal drugs such as alcohol and nicotine (Parrott et al, 2001). The drug usage patterns
from the current data set confirms that many of our Ecstasy users were illicit polydrug users
7(Scholey et al, submitted). Thus there were many potentially confounding factors, although it
must be emphasized that the current data are of attributions given to Ecstasy by the users
themselves. Further research is needed to investigate how they attribute their problems to
other psychoactive drugs, or to related factors.
In conclusion, the current findings demonstrate that self-reported psychobiological problems
attributed to Ecstasy, were a direct function of the amount of times it has been taken. A high
proportion of the heavy users complained of problems, but they were also reported by
substantial numbers of moderate users, and a smaller proportion of novice users (Table 1). It
should be noted that the more experienced users also tended to take more tablets on each
occasion, and reported higher maximum consumption rates (Scholey et al, submitted). The
nature of these problems was consistent with previous findings (McCann et al, 2000; Morgan,
2000; Parrott, 2000, 2001; Rodgers et al, 2001; Schifano et al, 1998; Topp et al, 1999). Some
of them may reflect rebound or 'come-down' effects, although others may well result from
longer-term serotonergic neurodegeneration (McCann et al, 2000; Ricaurte, et al, 2000;
Reneman et al, 2001). One topic for future research is to compare users who complain of
drug-related problems, with those who do not (Fox et al, 2001). It may be that the absence of
problems reflects a robust serotonergic system, a neuroprotective pattern of usage (eg.
avoidance of hyperthermia), or an atypical drug metabolism. Alternatively it may reflect poor
self-awareness, and/or a lack of recognition of the problems associated with chronic MDMA
use.
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Table 1. Novice, moderate, and heavy recreational Ecstasy/MDMA drug users (1-9, 10-99,
and +100 occasions). Percentage of each group reporting problems when drug-free, which
they attribute to the use of Ecstasy.
Ecstasy/MDMA user group Novice Moderate Heavy
Ecstasy usage (occasions) 1-9 10-99 +100
Sample size (N) 109 136 37
Mood and cognitive problems attributed to Ecstasy use. Chi-Square
Depression 33% 54% 65% 16.23 ***
Mood fluctuation 38% 70% 80% 31.21 ***
Impulsivity 18% 26% 32% 3.79 ns
Anxiety 32% 40% 60% 9.37 **
Poor Concentration 32% 62% 70% 29.80 ***
Memory Problems 19% 52% 73% 42.74 ***
Physiological and medical problems attributed to Ecstasy use. Chi-Square
Weight Loss 10% 37% 48% 28.99 ***
Infections 5% 9% 35% 24.94 ***
Tremors/Twitches 14% 20% 38% 9.95 **
Poor Sleep 37% 41% 52% 2.15 ns
Sexual Problems 7% 11% 22% 3.94 ns
2x3 Chi-Square analyses (df=2; two-tailed)) were performed on the yes/no responses from the
three groups. *** = P<0.001 **=p<0.01 ns = non-significant
